MARKET

ANNX

ANNX

Annexon, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.17
-1.72
-6.17%
Opening 11:54 01/20 EST
OPEN
28.00
PREV CLOSE
27.89
HIGH
28.21
LOW
25.63
VOLUME
46.17K
TURNOVER
--
52 WEEK HIGH
31.94
52 WEEK LOW
15.33
MARKET CAP
883.46M
P/E (TTM)
-27.3630
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Annexon Highlights Recent Achievements and Outlines Expected Key Milestones in 2021 for Its Broad Portfolio of Complement Therapeutics
Annexon, Inc. ("Annexon") (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, today highl...
GlobeNewswire · 01/12 15:00
Annexon Highlights Recent Achievements and Outlines Expected Key Milestones in 2021 for Its Broad Portfolio of Complement Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan 12, 2021 (GLOBE NEWSWIRE via COMTEX) -- SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc....
GlobeNewswire · 01/12 12:00
Annexon to Present at the J.P. Morgan 39th Annual Healthcare Conference
Annexon, Inc. ("Annexon") (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, today annou...
GlobeNewswire · 01/05 12:00
Annexon to Present at the J.P. Morgan 39th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neur...
GlobeNewswire · 01/05 12:00
Dosing underway in Annexon's Phase 2/3 study of monoclonal antibody in Guillain-Barré Syndrome
Annexon (ANNX) has commenced patient dosing in a Phase 2/3 trial of full-length monoclonal antibody, ANX005, to treat Guillain-Barré Syndrome ((GBS)), a rare, acute, antibody-mediated autoimmune disease that impacts the peripheral nervous
Seekingalpha · 12/21/2020 12:36
Annexon Announces Initiation of Phase 2/3 Trial of ANX005 in Patients with Guillain-Barré Syndrome
SOUTH SAN FRANCISCO, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Today, Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing novel therapies for patients with classical complement-mediated disorders of the brain, bo...
GlobeNewswire · 12/21/2020 12:00
Is ANNX A Good Stock To Buy Now?
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don’t make them change their opinion towards a company. This time it may be different. The coronavirus...
Insider Monkey · 12/11/2020 18:15
Annexon Biosciences EPS misses by $0.43
Annexon Biosciences (ANNX): Q3 GAAP EPS of -$0.77 misses by $0.43.Cash balance of $370.7M as of Sept. 30, 2020 bolstered by July IPO.Press Release
Seekingalpha · 11/16/2020 21:58
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ANNX. Analyze the recent business situations of Annexon, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ANNX stock price target is 34.50 with a high estimate of 37.00 and a low estimate of 32.00.
EPS
Institutional Holdings
Institutions: 65
Institutional Holdings: 34.79M
% Owned: 103.06%
Shares Outstanding: 33.76M
TypeInstitutionsShares
Increased
0
0
New
65
34.79M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.21%
Pharmaceuticals & Medical Research
+0.24%
Key Executives
Non-Executive Chairman/Independent Director
William Young
President/Chief Executive Officer/Director
Douglas Love
Chief Financial Officer/Executive Vice President
Jennifer Lew
Executive Vice President/Chief Scientific Officer
Ted Yednock
Executive Vice President
Sanjay Keswani
Executive Vice President
Michael Overdorf
Independent Director
Jung Choi
Independent Director
Emmett Cunningham
Independent Director
Carol Gallagher
Independent Director
Muneer Satter
Independent Director
Ricky Sun
Independent Director
Thomas Wiggans
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ANNX
Annexon, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of therapies for patients with classical complement-mediated disorders of the body, brain and eye. The Company’s pipeline is based on its platform technology addressing classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Its product candidate, ANX005, is a monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. Its product candidate, ANX007, is an antigen-binding fragment (Fab), formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. It is also developing ANX009, an investigational, subcutaneous formulation of a Fab designed for the treatment of systemic autoimmune diseases.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Annexon Inc stock information, including NASDAQ:ANNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANNX stock methods without spending real money on the virtual paper trading platform.